Literature DB >> 15496200

Two major histocompatibility complex haplotypes influence susceptibility to sporadic inclusion body myositis: critical evaluation of an association with HLA-DR3.

P Price1, L Santoso, F Mastaglia, M Garlepp, C C Kok, R Allcock, N Laing.   

Abstract

Previous studies of sporadic inclusion body myositis (sIBM) have shown a strong association with HLA-DR3 and other components of the 8.1 ancestral haplotype (AH) (HLA-A1, B8, DR3), where the susceptibility locus has been mapped to the central major histocompatibility complex (MHC) region between HLA-DR and C4. Here, the association with HLA-DR3 and other genes in the central MHC and class II region was further investigated in a group of 42 sIBM patients and in an ethnically similar control group (n = 214), using single-nucleotide polymorphisms and microsatellite screening. HLA-DR3 (marking DRB1*0301 in Caucasians) was associated with sIBM (Fisher's test). However, among HLA-DR3-positive patients and controls, carriage of HLA-DR3 without microsatellite and single-nucleotide polymorphism alleles of the 8.1AH (HLA-A1, B8, DRB3*0101, DRB1*0301, DQB1*0201) was marginally less common in patients. Patients showed no increase in carriage of the 18.2AH (HLA-A30, B18, DRB3*0202, DRB1*0301, DQB1*0201) or HLA-DR3 without the central MHC of the 8.1AH, further arguing against HLA-DRB1 as the direct cause of susceptibility. Genes between HLA-DRB1 and HOX12 require further investigation. BTL-II lies in this region and is expressed in muscle. Carriage of allele 2 (exon 6) was more common in patients. BTL-II(E6)*2 is characteristic of the 35.2AH (HLA-A3, B35, DRB1*01) in Caucasians and HLA-DR1, BTL-II(E6)*2, HOX12*2, RAGE*2 was carried by several patients. The 8.1AH and 35.2AH may confer susceptibility to sIBM independently or share a critical allele.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15496200     DOI: 10.1111/j.1399-0039.2004.00310.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  24 in total

1.  BTNL2, a butyrophilin-like molecule that functions to inhibit T cell activation.

Authors:  Thang Nguyen; Xikui K Liu; Yongliang Zhang; Chen Dong
Journal:  J Immunol       Date:  2006-06-15       Impact factor: 5.422

Review 2.  Gatekeepers of intestinal inflammation.

Authors:  Heather A Arnett; Joanne L Viney
Journal:  Inflamm Res       Date:  2010-01       Impact factor: 4.575

Review 3.  Sporadic inclusion body myositis: variability in prevalence and phenotype and influence of the MHC.

Authors:  F L Mastaglia
Journal:  Acta Myol       Date:  2009-10

4.  BTNL2-Ig Protein Attenuates Type 1 Diabetes in Non-Obese Diabetic (NOD) Mice.

Authors:  Xiaohong Tian; Yujun Lin; Cheng Cui; Min Su; Laijun Lai
Journal:  Adv Healthc Mater       Date:  2019-03-18       Impact factor: 9.933

Review 5.  The butyrophilin (BTN) gene family: from milk fat to the regulation of the immune response.

Authors:  Hassnae Afrache; Philippe Gouret; Shanaiz Ainouche; Pierre Pontarotti; Daniel Olive
Journal:  Immunogenetics       Date:  2012-09-23       Impact factor: 2.846

Review 6.  Immune modulation by butyrophilins.

Authors:  Heather A Arnett; Joanne L Viney
Journal:  Nat Rev Immunol       Date:  2014-08       Impact factor: 53.106

7.  Reassessing the role of HLA-DRB3 T-cell responses: evidence for significant expression and complementary antigen presentation.

Authors:  Rosa Faner; Eddie James; Laurie Huston; Ricardo Pujol-Borrel; William W Kwok; Manel Juan
Journal:  Eur J Immunol       Date:  2010-01       Impact factor: 5.532

8.  Association of genetic polymorphisms on BTNL2 with susceptibility to and prognosis of dilated cardiomyopathy in a Chinese population.

Authors:  Liang Cheng; Rong Zhao; ZhenXiao Jin; Kai Ren; Chao Deng; Shiqiang Yu
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 9.  [Myositides].

Authors:  A Bornemann; S Heitmann; A Lindner
Journal:  Pathologe       Date:  2009-09       Impact factor: 1.011

10.  How citation distortions create unfounded authority: analysis of a citation network.

Authors:  Steven A Greenberg
Journal:  BMJ       Date:  2009-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.